עקבו אחר הסרטון הבא כדי לצפות כיצד להתקין את האפליקציה של האתר על מסך הבית של המכשיר שברשותכם.
תזכורת: This feature may not be available in some browsers.
בולשיט ובגדול אחי, אין על סייקל אמיתי . לא מבין מה אנשים פתאום מחפשים הרפתקאות שנים מריצים סייקלים של טסט טרן דקה בולד ופתאום צץ משהו חדש gh בכדורים. ואז זה לא משפיע כמו שהורמון גדילה משפיע חוזרים לפה מתבכיינים ומתלוננים על מי שמכר להם. לא מדבר עליך פותח הפוסט אבל רק שתדע שפנו אליי כמה חברים שקנו ניסו והתאכזבו מהתוצאות. לא אומר שזה כך השפיע או משפיע על כולם אבל לפחות 6 חברים התבאסו . תנסה ותן חוות דעת פה בפורום זה הכי טובנראה כמו בולשיט. @Daniel Barack .
מה יש גל חדש עכשיו שרץ בארץ שכל פוסט שני הוא על sarms ,חח
פתאום צץ משהו חדש gh בכדורים
T Jacks et al. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles. Endocrinology, 1996, 137, 5284-5289.
MG Murphy et al. MK-677, an Orally Active Growth Hormone Secretagogue, Reverses Diet-Induced Catabolism. J. Clin. Endocrinol. Meta. 1998, 83, (2), 320-325.
LA Sorbera et al. Ibutamoren Mesylate. Drugs Fut. 2006, 31(5), 390.
E Codner et al. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone–insulin-like growth factor I axis in growth hormone–deficient children. Clin. Pharmacol. Ther. 2001, 70, 91–98.
Chapman, I.M. et al. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.J Clin Endocrinol Metab. 1997, 82(10), 3455-3463.
Hartman ML, Farello G, Pezzoli SS, Thorner MO. 1992 Oral administration of growth hormone (GH)-releasing peptide (GHRP) stimulates GH secretion in normal men. J Clin Endocrinol Metab. 74:1378–1384.
Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure
... Show more
The Journal of Clinical Endocrinology & Metabolism, Volume 83, Issue 2, 1 February 1998, Pages 362–369, Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure 1 | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic
Published:
01 February 1998
ABSTRACT
Obesity is associated with blunted GH secretion, unfavorable body composition, and increased cardiovascular mortality. The objective of this study was to investigate the effects of oral treatment with the GH secretagogue MK-677 on GH secretion and body composition in otherwise healthy obese males. The study was randomized, double blind, parallel, and placebo controlled. Twenty-four obese males, aged 18–50 yr, with body mass indexes greater than 30 kg/m2and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Serum insulin-like growth factor I (IGF-I) increased approximately 40% with MK-677 treatment (P < 0.001 vs. placebo). Serum IGF-binding protein-3 was also significantly increased (P ≤ 0.001 vs. placebo). GH and PRL (peak and area under the curve values) were significantly increased after the initial dose of MK-677. Significant increases, with the exception of peak PRL, persisted at 2 and 8 weeks of treatment. The increases in GH and PRL after the initial dose were significantly greater than the increase seen after multiple doses. Serum and urinary concentrations of cortisol were not increased at 2 and 8 weeks (P = NS, vs. placebo). Fat-free mass increased significantly in the MK-677 treatment group when determined with dual energy x-ray absorptiometry (P < 0.01) or using a four-compartment model (P < 0.05). Total and visceral fat were not significantly changed with active therapy. The basal metabolic rate was significantly increased at 2 weeks of MK-677 treatment (P = 0.01) but not at 8 weeks (P = 0.1). Fasting concentrations of glucose and insulin were unchanged, whereas an oral glucose tolerance test showed impairment of glucose homeostasis at 2 and 8 weeks.
We conclude that 2-month treatment with MK-677 in healthy obese males caused a sustained increase in serum levels of GH, IGF-I, and IGF-binding protein-3. The effects on cortisol secretion were transient. Changes in body composition and energy expenditure were of an anabolic nature, with a sustained increase in fat-free mass and a transient increase in basal metabolic rate. Further studies are needed to evaluate whether a higher dose of MK-677 or a more prolonged treatment period can promote a reduction in body fat.
MK-677, an Orally Active Growth Hormone Secretagogue, Reverses Diet-Induced Catabolism
MK-677, an Orally Active Growth Hormone Secretagogue, Reverses Diet-Induced Catabolism 1 | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic
Published:
01 February 1998
The reversal of diet-induced negative nitrogen balance by GH suggests a possible therapeutic role for GH treatment in catabolic patients. A double-blind, randomized, placebo-controlled, two-period, cross-over study was designed to investigate whether MK-677, an orally active nonpeptide mimic of GH-releasing peptide, can reverse diet-induced protein catabolism. Eight healthy volunteers (ages 24–39 yr) were calorically restricted (18 kcal/kg·day) for two 14-day periods. During the last 7 days of each diet period, subjects received either oral MK-677 25 mg or placebo once daily. There was a 14- to 21-day washout interval between periods. During the first week of caloric restriction (i.e. diet alone), daily nitrogen losses were similar for both treatment groups (mean ± SE; MK-677 group −2.67 ± 0.40 g/day vs. placebo group− 2.83 ± 0.26 g/day). During the second week (diet and study drug), mean daily nitrogen balance was 0.31 ± 0.21 g/day in the MK-677 treatment group compared with −1.48 ± 0.21 g/day in the placebo group (P < 0.01). MK-677 improved nitrogen balance integrated over the 7 days of treatment; area under the curve day 8–14 nitrogen balance response was +2.69 ± 5.0 (SE) for MK-677 and −8.97 ± 5.26 g·day for placebo (P < 0.001). MK-677 produced a peak GH response of 55.9 ± 31.7 μg/L after single dose (day 1 of treatment) and 22.6 ± 9.3 μg/L after a week of dosing compared with placebo treatment peak GH values of approximately 9 (treatment day 1) and approximately 7 μg/L (treatment day 7). Following the initial 7-day caloric restriction, insulin-like growth factor-I (IGF-I) declined from 232 ± 25 to 186 ± 19 ng/mL in the MK-677 group and from 236 ± 19 to 174 ± 23 ng/mL in the placebo group. Mean IGF-I concentration increased significantly during MK-677 to 264 ± 31 ng/mL (mean for the last 5 days of treatment) compared with 188 ± 19 ng/mL with placebo (P < 0.01). No significant difference in IGF binding protein-2 was found between the MK-677 and placebo treatments. However, the mean in IGF binding protein-3 for the last 5 days of MK-677 treatment was also significantly increased to 3273 ± 330 ng/mL (mean ± SE) compared with placebo 2604 ± 253 ng/mL (P < 0.01). Neither the serum cortisol nor the PRL response was significantly greater after 7 days of MK-677 dosing compared with 7 days of placebo. MK-677 (25 mg) was generally well tolerated and without clinically significant adverse experiences. In conclusion, MK-677 reverses diet-induced nitrogen wasting, suggesting that if these short-term anabolic effects are maintained in patients who are catabolic because of certain acute or chronic disease states, it may be useful in treating catabolic conditions.
בולשיט ובגדול אח
זה לא משפיע כמו שהורמון גדילה משפיע חוזרים לפה מתבכיינים ומתלוננים על מי שמכר להם
אבל רק שתדע שפנו אליי כמה חברים שקנו ניסו והתאכזבו מהתוצאות
להריץ את זה סולו לא יתן לך שום דבר חוץ מכאבי בטן, נפיחות ופאמפ קטן במכון.
אני מעדיף להזריק טסט וטרן ולא לגעת במשהו שיעשה לי כאבי בטן *
לי לא עושה בכלל , חוץ מחום גוף טיפה שעולה וזיעה בלילה נותן לי כח מטורף באימונים והתאוששות מהירה. מה גם שאני אוכל כמו מטורף. לא כל אחד נהנה מימנו אני כן, אולי אני מזוכיסט חחטרן גורם לצרבות אם אתה מחשיב את זה לסוג של כאב בטן.. =)